electro-optical sciences, inc.

Investor Fact Sheet

EOS is developing a non-invasive, point-of-care instrument to assist physicians in the early diagnosis of melanoma. Our flagship product is MelaFind®, a hand-held imaging device that emits light of multiple wavelengths to capture images of suspicious pigmented skin lesions. Physicians are provided with important information regarding the patient's suspicious pigmented skin lesions that is not available from current methodologies.

EOS has entered into a binding Protocol Agreement with the US Food and Drug Administration (FDA) to conduct a pivotal trial to establish the safety and effectiveness of MelaFind. The pivotal trial began in January 2007. The FDA has informed EOS that, when submitted, the MelaFind premarket approval (PMA) application would receive expedite review.

In March 2007, EOS entered into a Research and Feasibility Agreement with L'Oreal to study and assess the feasibility of using EOS' novel multi-spectral imaging technology for the evaluation and differentiation of pigmented skin lesions of cosmetic importance.

Investment Highlights:

- MelaFind is a product for assisting in early melanoma detection and has the capacity to meet an unmet medical need
- Strong clinical trial results with more than 3,500 patients studied
- FDA Protocol Agreement and Expedited Review upon PMA Submission
- MelaFind is intended to provide recurring revenue based on the number of patients examined

Melanoma Facts

- The incidence of skin cancer is greater than all other cancers combined.
- 1.3 million skin cancer cases were projected annually for 2007
  - 120,000 new melanoma cases projected annually for 2007
  - Melanoma is the fastest growing cancer
  - Melanoma is the leading cause of cancer death in women ages 25-30
- Melanoma is the deadliest of skin cancers, responsible for approximately 75% of all skin cancer deaths.
- There is no cure for advanced stage melanoma

The MelaFind System

- Components of the MelaFind system include:
- A *hand-held imaging device;*
- Our *proprietary database* of skin lesions, which we believe is the largest in the US;
- *Lesion classifiers,* which extract lesion feature information and classify lesions; and;
- A per-patient examination card for system activation and data archiving

Clinical Results to Date

In the largest blinded trial that we have performed to date on 562 suspicious pigmented skin lesions, MelaFind missed a single melanoma in situ while study dermatologists detected 53 of 54 melanomas, but missed an invasive melanoma. MelaFind achieved specificity of 45.1% compared with specificity of 20.0% ($p < 0.0001$) achieved by study dermatologists. ("Specificity" is the ability to exclude disease when disease is not present).

EOS expects that MelaFind will have been developed and tested on approximately 7,000 pigmented skin lesions from 5,000 patients upon PMA submission.

The EOS Advantage



Traditional visual clinical examination is limited to the surface appearance of the suspicious pigmented skin lesion. MelaFind uses an illuminator that shines light of multiple wavelengths up to 2.5 mm deep into the skin.

❖ EOS Team

- Joseph V. Gulfo, M.D., M.B.A., CEO
- Richard I. Steinhart, C.P.A., CFO
- Dina Gutkowicz-Krusin, Ph.D., Principal Scientist
- Nicholai Kabelev, VP R&D
- Tina Cheng-Avery, VP Commercialization
- Christiano Butler, VP Operations
- Jon I. Klippel, VP Marketing Operations

❖ EOS VITALS

NASDAQ CM: MELA
Shares Outstanding: 15.4 million
Market Cap: $67.92 million
(as of January 14, 2008)
Employees: 30

❖ EOS Corporate Headquarters

3 West Main Street; Suite 201
Irvington, N.Y. 10533
Tel: 914-591-3783
E-mail: info@eosciences.com
Website: www.eosciences.com

Analyst Coverage:

Dalton Chandler – Needham & Co.
Matt Dolan – Roth Capital Partners
Stephan Ogilvie – ThinkEquity Partners

For additional information:

David Carey
Lazar Partners
Tel: (212) 867-1762
dcarey@lazarpartners.com

Corporate Strategy

- ❖ Pursue timely FDA approval of MelaFind
- ❖ Establish MelaFind as the leading technology for assisting in the detection of melanoma
- ❖ Obtain 3rd party reimbursement to support recurring revenue pricing model
- ❖ Commercialize MelaFind
- ❖ Develop additional products based on MelaFind's technology:
  - ➢ **ABCD Device** – to be used by patients and non-dermatologists to identify pigmented skin lesions having suspicious characteristics warranting evaluation by experts. (patent filed 3/2/07)
  - ➢ **MelaMeter™** - to provide additional information at point of care regarding the depth of penetration of a pigmented skin lesion.

Expected Milestones

- ❖ Completion of pivotal trial – 1H 2008
- ❖ PMA submission to the FDA – Mid-2008

Recent News

January 10, 2008 – EOS Announces Pivotal Trial Two-Thirds Complete

The MelaFind hand-held imaging device

www.eosciences.com